Literature DB >> 21480233

Role of RNA binding protein HuR in ductal carcinoma in situ of the breast.

Mira Heinonen1, Annabrita Hemmes, Kaisa Salmenkivi, Kotb Abdelmohsen, Suvi-Tuuli Vilén, Marko Laakso, Marjut Leidenius, Tuula Salo, Sampsa Hautaniemi, Myriam Gorospe, Päivi Heikkilä, Caj Haglund, Ari Ristimäki.   

Abstract

HuR is a ubiquitously expressed RNA-binding protein that modulates gene expression at the post-transcriptional level. It is predominantly nuclear, but can shuttle between the nucleus and the cytoplasm. While in the cytoplasm HuR can stabilize its target transcripts, many of which encode proteins involved in carcinogenesis. While cytoplasmic HuR expression is a marker of reduced survival in breast cancer, its role in precursor lesions of malignant diseases is unclear. To address this we explored HuR expression in atypical ductal hyperplasia (ADH) and in ductal in situ carcinomas (DCIS). We show that cytoplasmic HuR expression is elevated in both ADH and DCIS when compared to normal controls, and that this expression associated with high grade, progesterone receptor negativity and microinvasion and/or tumour-positive sentinel nodes of the DCIS. To study the mechanisms of HuR in breast carcinogenesis, HuR expression was silenced in an immortalized breast epithelial cell line (184B5Me), which led to reduction in anchorage-independent growth, increased programmed cell death and inhibition of invasion. In addition, we identified two novel target transcripts (CTGF and RAB31) that are regulated by HuR and that bind HuR protein in this cell line. Our results show that HuR is aberrantly expressed at early stages of breast carcinogenesis and that its inhibition can lead to suppression of this process. ArrayExpress Accession No. E-MEXP-3035.
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21480233      PMCID: PMC3504799          DOI: 10.1002/path.2889

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  44 in total

Review 1.  Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence.

Authors:  Kotb Abdelmohsen; Yuki Kuwano; Hyeon Ho Kim; Myriam Gorospe
Journal:  Biol Chem       Date:  2008-03       Impact factor: 3.915

2.  Identification of transformation-related pathways in a breast epithelial cell model using a ribonomics approach.

Authors:  Krystyna Mazan-Mamczarz; Patrick R Hagner; Bojie Dai; William H Wood; Yongqing Zhang; Kevin G Becker; Zhenqui Liu; Ronald B Gartenhaus
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

3.  Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor.

Authors:  Matthias Kotzsch; Anieta M Sieuwerts; Marianne Grosser; Axel Meye; Susanne Fuessel; Marion E Meijer-van Gelder; Marcel Smid; Manfred Schmitt; Gustavo Baretton; Thomas Luther; Viktor Magdolen; John A Foekens
Journal:  Breast Cancer Res Treat       Date:  2007-10-20       Impact factor: 4.872

Review 4.  Diverse molecular functions of Hu proteins.

Authors:  M N Hinman; H Lou
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

5.  Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells.

Authors:  Christine Hostetter; Lauren A Licata; Agnieszka Witkiewicz; Christina L Costantino; Charles J Yeo; Jonathan R Brody; Judith Clancy Keen
Journal:  Cancer Biol Ther       Date:  2008-09-23       Impact factor: 4.742

6.  Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II.

Authors:  Jin-Song Wang; Fu-Bin Wang; Qiang-Ge Zhang; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

7.  Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype.

Authors:  K Mazan-Mamczarz; P R Hagner; S Corl; S Srikantan; W H Wood; K G Becker; M Gorospe; J D Keene; A S Levenson; R B Gartenhaus
Journal:  Oncogene       Date:  2008-07-21       Impact factor: 9.867

8.  Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.

Authors:  Gary K Scott; Corina Marx; Crystal E Berger; Laura R Saunders; Eric Verdin; Stefan Schäfer; Manfred Jung; Christopher C Benz
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

9.  Prognostic role of HuR in hereditary breast cancer.

Authors:  Mira Heinonen; Rainer Fagerholm; Kirsimari Aaltonen; Outi Kilpivaara; Kristiina Aittomäki; Carl Blomqvist; Päivi Heikkilä; Caj Haglund; Heli Nevanlinna; Ari Ristimäki
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

10.  Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.

Authors:  Hongshen Guo; Yifeng Lin; Hongwei Zhang; Juan Liu; Nong Zhang; Yiming Li; Desheng Kong; Qiqun Tang; Duan Ma
Journal:  BMC Mol Biol       Date:  2007-12-03       Impact factor: 2.946

View more
  21 in total

1.  Elevated Hu-Antigen Receptor (HuR) Expression is Associated with Tumor Aggressiveness and Poor Prognosis but not with COX-2 Expression in Invasive Breast Carcinoma Patients.

Authors:  Constantinos Giaginis; Anastasia Sampani; Iolly Kotta-Loizou; Ioanna Giannopoulou; Eugene Danas; Ekaterini Politi; Gerasimos Tsourouflis; Gregorios Kouraklis; Efstratios Patsouris; Antonios Keramopoulos; Lydia Nakopoulou; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2017-08-14       Impact factor: 3.201

Review 2.  Clinical significance of HuR expression in human malignancy.

Authors:  Ioly Kotta-Loizou; Constantinos Giaginis; Stamatios Theocharis
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

Review 3.  Regulation of the mRNA half-life in breast cancer.

Authors:  Paola Griseri; Gilles Pagès
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  Cytoplasmic expression of the ELAV-like protein HuR as a potential prognostic marker in esophageal squamous cell carcinoma.

Authors:  Cong Zhang; Guoliang Xue; Jingwang Bi; Ming Geng; Huili Chu; Yaping Guan; Jun Wang; Baocheng Wang
Journal:  Tumour Biol       Date:  2013-07-20

5.  Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer.

Authors:  Zhongpeng Zhu; Baocheng Wang; Jingwang Bi; Cong Zhang; Yan Guo; Huili Chu; Xiuju Liang; Chen Zhong; Jun Wang
Journal:  Tumour Biol       Date:  2013-04-19

Review 6.  Sorting out functions of sirtuins in cancer.

Authors:  M Roth; W Y Chen
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

7.  Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.

Authors:  Matthias Kotzsch; Thomas Kirchner; Susanne Soelch; Sonja Schäfer; Katrin Friedrich; Gustavo Baretton; Viktor Magdolen; Thomas Luther
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

8.  Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells.

Authors:  Bettina Grismayer; Susanne Sölch; Bastian Seubert; Thomas Kirchner; Sonja Schäfer; Gustavo Baretton; Manfred Schmitt; Thomas Luther; Achim Krüger; Matthias Kotzsch; Viktor Magdolen
Journal:  Mol Cancer       Date:  2012-08-24       Impact factor: 27.401

Review 9.  Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis.

Authors:  Jun Wang; Yan Guo; Huili Chu; Yaping Guan; Jingwang Bi; Baocheng Wang
Journal:  Int J Mol Sci       Date:  2013-05-10       Impact factor: 5.923

10.  miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer.

Authors:  Wijdan Al-Ahmadi; Maha Al-Ghamdi; Norah Al-Souhibani; Khalid S A Khabar
Journal:  J Pathol       Date:  2013-03-21       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.